Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2005

View Archived Issues

AstraZeneca: second quarter highlights

NBI-59159: Novel EAAT3 preferring inhibitor from Wyeth

New data on the efficacy of sitaxsentan in PAH

A-778193 reduced food intake and body weight via GHS-R antagonism

MicroIslet and Scripps Research Institute extend diabetes collaboration

Epitan obtains ethics approval for phase II study of EPT-1647 for PMLE

Encouraging outcomes for pilot study of Aerosurf delivered via nasal CPAP

In vitro and in vivo data on novel HIV integrase inhibitor

Accera receives approval for Ketasyn extension study

ImClone to use Medarex's UltiMAb system to develop human antibody products

Zonagen awards contracts for studies of Proellex and Androxal

Daiichi and GE Healthcare team up on non-nuclear contrast media

New insulin secretagogues for diabetes reported in recent Takeda patent

Recent patents cover novel therapeutics for anxiety, depression, etc.

Novel therapeutics for cardiovascular diseases reported

Ularitide has beneficial clinical effects in decompensated heart failure patients

BL-1020 targets GABA hypoactivity and dopamine overactivity for schizophrenia

Neuronal Kv7 channels: new targets for anxiolytics

New DPP-IV inhibitor highlighted as a therapeutic candidate for type 2 diabetes

New clinical evidence supports using oral insulin spray to improve glycemic control in diabetics

Priority review for Pegasys plus ribavirin in Japan

BXL-628 demonstrates efficacy in experimental autoimmune prostatitis

Nonapprovable letter for lasofoxifene in prevention of osteoporosis

Aromasin approved in Europe for adjuvant treatment of early breast cancer

Eisai submits NDA for antiepileptic agent rufinamide

ODAC recommends approval of Tarceva for pancreatic cancer

FDA committee does not recommend Xinlay

Antioxidant L-2264 ameliorates metabolic impairment in rats with insulin resistance

Data on quadrivalent human papillomavirus vaccine accumulate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...